Pharma Mar, S.A. (PHMMF)
USD 88.18
(-16.49%)
USD 88.18
(-16.49%)
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2023 | 341.22 Million EUR | -13.23% |
| 2022 | 393.25 Million EUR | 6.75% |
| 2021 | 368.38 Million EUR | 11.54% |
| 2020 | 330.25 Million EUR | 164.83% |
| 2019 | 124.7 Million EUR | -20.91% |
| 2018 | 157.67 Million EUR | -16.0% |
| 2017 | 187.72 Million EUR | -15.11% |
| 2016 | 221.13 Million EUR | 4.34% |
| 2015 | 211.93 Million EUR | 5.24% |
| 2014 | 201.38 Million EUR | 6.35% |
| 2013 | 189.37 Million EUR | -5.23% |
| 2012 | 199.83 Million EUR | -8.26% |
| 2011 | 217.81 Million EUR | -5.64% |
| 2010 | 230.82 Million EUR | 9.23% |
| 2009 | 211.31 Million EUR | 1.82% |
| 2008 | 207.54 Million EUR | -10.67% |
| 2007 | 232.32 Million EUR | 3.53% |
| 2006 | 224.4 Million EUR | -43.0% |
| 2005 | 393.72 Million EUR | 16.71% |
| 2004 | 337.33 Million EUR | 22.46% |
| 2003 | 275.47 Million EUR | 1.49% |
| 2002 | 271.43 Million EUR | 0.0% |
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2024 Q3 | 333.12 Million EUR | 5.05% |
| 2024 Q1 | 333.89 Million EUR | -2.15% |
| 2024 Q2 | 317.1 Million EUR | -5.03% |
| 2023 Q4 | 341.22 Million EUR | -2.34% |
| 2023 Q2 | 358.69 Million EUR | -4.02% |
| 2023 Q3 | 349.41 Million EUR | -2.59% |
| 2023 Q1 | 373.71 Million EUR | -4.97% |
| 2023 FY | 341.22 Million EUR | -13.23% |
| 2022 Q3 | 379.09 Million EUR | -2.99% |
| 2022 Q4 | 393.25 Million EUR | 3.74% |
| 2022 FY | 393.25 Million EUR | 6.75% |
| 2022 Q1 | 378.02 Million EUR | 2.62% |
| 2022 Q2 | 390.77 Million EUR | 3.37% |
| 2021 Q4 | 368.38 Million EUR | 5.95% |
| 2021 FY | 368.38 Million EUR | 11.54% |
| 2021 Q2 | 342.54 Million EUR | -0.74% |
| 2021 Q1 | 345.1 Million EUR | 4.49% |
| 2021 Q3 | 347.69 Million EUR | 1.5% |
| 2020 Q3 | 329.73 Million EUR | -6.39% |
| 2020 Q2 | 352.22 Million EUR | 27.8% |
| 2020 Q1 | 275.61 Million EUR | 121.01% |
| 2020 FY | 330.25 Million EUR | 164.83% |
| 2020 Q4 | 330.25 Million EUR | 0.16% |
| 2019 Q1 | 166.1 Million EUR | 5.34% |
| 2019 Q3 | 112.53 Million EUR | -13.26% |
| 2019 Q4 | 124.7 Million EUR | 10.81% |
| 2019 FY | 124.7 Million EUR | -20.91% |
| 2019 Q2 | 129.73 Million EUR | -21.89% |
| 2018 Q1 | 185.64 Million EUR | -1.1% |
| 2018 Q4 | 157.67 Million EUR | -9.82% |
| 2018 Q3 | 174.85 Million EUR | -8.27% |
| 2018 FY | 157.67 Million EUR | -16.0% |
| 2018 Q2 | 190.61 Million EUR | 2.68% |
| 2017 Q1 | 216.64 Million EUR | -2.03% |
| 2017 FY | 187.72 Million EUR | -15.11% |
| 2017 Q3 | 202.71 Million EUR | -8.77% |
| 2017 Q2 | 222.19 Million EUR | 2.56% |
| 2017 Q4 | 187.72 Million EUR | -7.39% |
| 2016 Q4 | 221.13 Million EUR | 5.54% |
| 2016 Q3 | 209.52 Million EUR | -4.99% |
| 2016 FY | 221.13 Million EUR | 4.34% |
| 2016 Q2 | 220.53 Million EUR | 1.17% |
| 2016 Q1 | 217.99 Million EUR | 2.86% |
| 2015 FY | 211.93 Million EUR | 5.24% |
| 2015 Q4 | 211.93 Million EUR | -13.74% |
| 2015 Q1 | 205.77 Million EUR | 2.18% |
| 2015 Q2 | 223.1 Million EUR | 8.43% |
| 2015 Q3 | 245.69 Million EUR | 10.12% |
| 2014 Q3 | 213.55 Million EUR | -2.95% |
| 2014 Q4 | 201.38 Million EUR | -5.7% |
| 2014 Q2 | 220.04 Million EUR | 7.23% |
| 2014 Q1 | 205.2 Million EUR | 8.36% |
| 2014 FY | 201.38 Million EUR | 6.35% |
| 2013 FY | 189.37 Million EUR | -5.23% |
| 2013 Q1 | 216.48 Million EUR | 8.33% |
| 2013 Q2 | 207.36 Million EUR | -4.21% |
| 2013 Q3 | 201.86 Million EUR | -2.65% |
| 2013 Q4 | 189.37 Million EUR | -6.19% |
| 2012 Q3 | 218.47 Million EUR | -5.21% |
| 2012 Q1 | 212.2 Million EUR | -2.58% |
| 2012 FY | 199.83 Million EUR | -8.26% |
| 2012 Q2 | 230.49 Million EUR | 8.62% |
| 2012 Q4 | 199.83 Million EUR | -8.53% |
| 2011 Q4 | 217.81 Million EUR | -1.45% |
| 2011 FY | 217.81 Million EUR | -5.64% |
| 2011 Q3 | 221.02 Million EUR | -2.94% |
| 2011 Q1 | 220.88 Million EUR | -4.3% |
| 2011 Q2 | 227.72 Million EUR | 3.09% |
| 2010 Q4 | 230.82 Million EUR | -3.24% |
| 2010 Q1 | 215.98 Million EUR | 2.21% |
| 2010 Q3 | 238.55 Million EUR | -1.72% |
| 2010 Q2 | 242.72 Million EUR | 12.38% |
| 2010 FY | 230.82 Million EUR | 9.23% |
| 2009 Q2 | 231.05 Million EUR | 12.08% |
| 2009 Q4 | 211.31 Million EUR | -7.54% |
| 2009 FY | 211.31 Million EUR | 1.82% |
| 2009 Q3 | 228.53 Million EUR | -1.09% |
| 2009 Q1 | 206.15 Million EUR | -0.67% |
| 2008 Q4 | 207.54 Million EUR | 0.0% |
| 2008 FY | 207.54 Million EUR | -10.67% |
| 2007 FY | 232.32 Million EUR | 3.53% |
| 2006 FY | 224.4 Million EUR | -43.0% |
| 2005 FY | 393.72 Million EUR | 16.71% |
| 2004 FY | 337.33 Million EUR | 22.46% |
| 2003 FY | 275.47 Million EUR | 1.49% |
| 2002 FY | 271.43 Million EUR | 0.0% |
| Name | Total Assets | Total Assets Difference |
|---|---|---|
| Bioxytran, Inc. | 137.63 Thousand USD | -247813.367% |
| Eiger BioPharmaceuticals, Inc. | 38.84 Million USD | -778.377% |
| Institute of Biomedical Research Corp. | 76.35 Thousand USD | -446796.037% |
| SQZ Biotechnologies Company | 107.18 Million USD | -218.344% |
| Intellipharmaceutics International Inc. | 1.43 Million USD | -23727.889% |
| Evofem Biosciences, Inc. | 10.55 Million USD | -3133.115% |
| Santhera Pharmaceuticals Holding AG | 130.21 Million USD | -162.054% |
| Propanc Biopharma, Inc. | 72.36 Thousand USD | -471430.436% |
| Marizyme, Inc. | 22.01 Million USD | -1449.952% |
| Genus plc | 1.02 Billion USD | 66.836% |
| Pharming Group N.V. | 462.85 Million USD | 26.278% |
| Therapeutic Solutions International, Inc. | 3.31 Million USD | -10199.48% |
| CNBX Pharmaceuticals Inc. | 499.03 Thousand USD | -68276.019% |
| Nymox Pharmaceutical Corporation | 627 Thousand USD | -54321.531% |
| ContraFect Corporation | 20.67 Million USD | -1550.094% |
| RegeneRx Biopharmaceuticals, Inc. | 382.17 Thousand USD | -89184.023% |
| IMV Inc. | 31.33 Million USD | -988.994% |
| AXIM Biotechnologies, Inc. | 4.14 Million USD | -8130.13% |
| ONE Bio Corp. | 70.08 Million USD | -386.867% |
| RVL Pharmaceuticals plc | 128.51 Million USD | -165.523% |
| Mesoblast Limited | 667.9 Million USD | 48.911% |
| MultiCell Technologies, Inc. | 126.22 USD | -270339782.744% |
| Arno Therapeutics, Inc. | - USD | -Infinity% |
| Emmaus Life Sciences, Inc. | 35.17 Million USD | -869.962% |
| Genscript Biotech Corporation | 3.38 Billion USD | 89.924% |
| Neon Bloom, Inc. | 770.64 Thousand USD | -44177.643% |
| Mosaic ImmunoEngineering Inc. | 261.27 Thousand USD | -130498.177% |
| Nanobac Pharmaceuticals, Incorporated | 7.21 Million USD | -4626.236% |
| Biomind Labs Inc. | 73.81 Thousand USD | -462142.783% |
| Provectus Biopharmaceuticals, Inc. | 1.44 Million USD | -23451.413% |
| Oncotelic Therapeutics, Inc. | 30.01 Million USD | -1036.843% |
| Skye Bioscience, Inc. | 11.94 Million USD | -2757.716% |
| GlobeStar Therapeutics Corporation | - USD | -Infinity% |
| VioQuest Pharmaceuticals, Inc. | 1.35 Million USD | -25020.348% |
| THC Farmaceuticals, Inc. | 2.74 Million USD | -12324.668% |
| PsyBio Therapeutics Corp. | 390.36 Thousand USD | -87311.045% |
| Arch Therapeutics, Inc. | 1.95 Million USD | -17325.437% |
| Sienna Biopharmaceuticals, Inc. | - USD | -Infinity% |
| Acro Biomedical Co., Ltd. | 687.48 Thousand USD | -49533.447% |
| Accustem Sciences Inc. | 939.68 Thousand USD | -36212.333% |
| EV Biologics, Inc. | 431.71 Thousand USD | -78939.132% |
| Q BioMed Inc. | 3.51 Million USD | -9606.197% |
| GB Sciences, Inc. | 103.44 Thousand USD | -329768.912% |
| Alpha Cognition Inc. | 2.45 Million USD | -13815.145% |
| CSL Limited | 38.02 Billion USD | 99.103% |
| Agentix Corp. | 261.39 Thousand USD | -130440.72% |
| American Oriental Bioengineering, Inc. | 446.3 Million USD | 23.546% |
| Enzolytics Inc. | 361.7 Million USD | 5.663% |
| TetraLogic Pharmaceuticals Corporation | - USD | -Infinity% |
| Resverlogix Corp. | 8.11 Million USD | -4104.843% |
| Nuo Therapeutics, Inc. | 1.87 Million USD | -18070.65% |
| MetaStat, Inc. | - USD | -Infinity% |
| Curative Biotechnology, Inc. | 2.6 Million USD | -13007.849% |
| argenx SE | 4.54 Billion USD | 92.488% |
| Northwest Biotherapeutics, Inc. | 27.94 Million USD | -1121.096% |
| HST Global, Inc. | 1526.00 USD | -22360515.99% |
| Enzon Pharmaceuticals, Inc. | 47.7 Million USD | -615.322% |
| Wesana Health Holdings Inc. | 987.96 Thousand USD | -34437.894% |
| Halberd Corporation | 10.13 Thousand USD | -3368007.788% |
| Endonovo Therapeutics, Inc. | 639.65 Thousand USD | -53244.767% |
| Inhibitor Therapeutics, Inc. | 8.94 Million USD | -3712.907% |
| Zenith Capital Corp. | 7410.00 USD | -4604798.785% |
| RespireRx Pharmaceuticals Inc. | 22.78 Thousand USD | -1497740.306% |
| GeneThera, Inc. | - USD | -Infinity% |
| Sigyn Therapeutics, Inc. | 321.8 Thousand USD | -105933.759% |
| AVAX Technologies, Inc. | 7.37 Million USD | -4525.4% |
| WPD Pharmaceuticals Inc. | 261.36 Thousand USD | -130454.705% |
| Cotinga Pharmaceuticals Inc. | 927.96 Thousand USD | -36671.265% |
| Ember Therapeutics, Inc. | 184.00 USD | -185447182.609% |
| Anthera Pharmaceuticals, Inc. | - USD | -Infinity% |
| Adynxx, Inc. | - USD | -Infinity% |
| NovAccess Global Inc. | 62.24 Thousand USD | -548067.009% |
| Helix BioMedix, Inc. | 3.02 Million USD | -11179.778% |
| Capstone Therapeutics Corp. | 52.7 Million USD | -547.47% |
| Kadimastem Ltd | 2.3 Million USD | -14709.512% |
| VitaSpring Biomedical Co. Ltd. | - USD | -Infinity% |
| BioStem Technologies, Inc. | 14.56 Million USD | -2243.518% |
| Oncology Pharma Inc. | - USD | -Infinity% |
| Reve Technologies, Inc. | 57.09 Thousand USD | -597551.242% |
| Burzynski Research Institute, Inc. | 2310.00 USD | -14771458.442% |
| LadRx Corporation | 2.3 Million USD | -14685.115% |
| Cell Source, Inc. | 195.17 Thousand USD | -174732.839% |
| ProtoKinetix, Incorporated | 480.55 Thousand USD | -70905.729% |
| Regen BioPharma, Inc. | 353.61 Thousand USD | -96395.078% |
| Regen BioPharma, Inc. | 353.61 Thousand USD | -96395.078% |
| Affymax, Inc. | 7.44 Million USD | -4484.482% |
| Mobile Lads Corp. | 52.00 USD | -656197976.923% |
| Itoco Inc. | 1.4 Million USD | -24271.818% |
| Rasna Therapeutics, Inc. | 95.65 Thousand USD | -356615.138% |
| Pathfinder Cell Therapy, Inc. | 106 Thousand USD | -321808.491% |
| International Stem Cell Corporation | 5.39 Million USD | -6230.668% |
| CytoDyn Inc. | 11.13 Million USD | -2964.143% |
| Claritas Pharmaceuticals, Inc. | - USD | -Infinity% |
| NDT Pharmaceuticals Inc. | 142.97 Thousand USD | -238564.214% |
| NanoSphere Health Sciences Inc. | 17.88 Thousand USD | -1908306.04% |
| Qrons Inc. | 420.00 USD | -81243471.429% |
| Alseres Pharmaceuticals, Inc. | 385.47 Thousand USD | -88421.056% |
| SYBLEU INC | 330.46 Thousand USD | -103154.475% |
| Advanced Proteome Therapeutics Corporation | - USD | -Infinity% |
| Nascent Biotech, Inc. | 552.12 Thousand USD | -61702.326% |
| Rebus Holdings, Inc. | 5000.00 USD | -6824360.0% |
| GlobeImmune, Inc. | - USD | -Infinity% |
| ImmunoCellular Therapeutics, Ltd. | 409.42 Thousand USD | -83242.615% |
| Predictive Technology Group, Inc. | - USD | -Infinity% |
| ProText Mobility, Inc. | 15 Million USD | -2174.543% |
| Cardax, Inc. | - USD | -Infinity% |
| VG Life Sciences Inc. | - USD | -Infinity% |
| Kaleido Biosciences, Inc. | - USD | -Infinity% |
| Advaxis, Inc. | 16.57 Million USD | -1958.164% |
| Adhera Therapeutics, Inc. | 79 Thousand USD | -431827.848% |
| RenovaCare, Inc. | - USD | -Infinity% |
| Regnum Corp. | 864.67 Thousand USD | -39362.481% |
| Innovation Pharmaceuticals Inc. | 7.51 Million USD | -4439.351% |
| Neutra Corp. | 2851.00 USD | -11968437.355% |
| Windtree Therapeutics, Inc. | 32.4 Million USD | -952.962% |
| PureTech Health plc | 693.97 Million USD | 50.831% |
| Coeptis Therapeutics, Inc. | 8.07 Million USD | -4127.719% |
| IXICO plc | 15.84 Million USD | -2053.655% |
| IntelGenx Technologies Corp. | 8.28 Million USD | -4020.056% |
| Gelesis Holdings, Inc. | 103.32 Million USD | -230.246% |
| CSL Limited | 38.02 Billion USD | 99.103% |
| Cellectis S.A. | 333.99 Million USD | -2.164% |